DLA Piper advises Jones in Elicio Therapeutics’ US$40 million ATM and US$11.5 million public offering

DLA Piper advised JonesTrading Institutional Services (Jones), a leading broker dealer and investment bank, as agent in a US$40 million Capital on DemandTM at-the-market (ATM) offering of common stock and as sole book-running manager in a US$11.5 million underwritten public offering of common stock, pre-funded warrants and warrants for Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. The ATM went effective on June 11, 2024 and the underwritten offering closed on July 1, 2024.

“We are pleased to have advised Jones as sales agent/underwriter of Elicio’s securities based on our biopharmaceutical industry expertise, capital markets prowess and strong bank-side credentials,” said Josh Kaufman (New York/Miami), co-chair of DLA Piper’s Capital Markets and Public Companies Advisory Practice, who led the deal team with partner Stephen Alicanti (New York).

The DLA Piper team also included partner Christopher Mikson (Washington DC) and associates Kim McKenzie (Raleigh) and Sarah Cooper (Seattle).

DLA Piper’s global capital markets team represents issuers and underwriters in registered and unregistered equity, equity-linked and debt capital markets transactions, including initial public offerings, follow-on equity offerings, equity-linked securities offerings, and offerings of investments grade and high-yield debt securities.